![]() | ![]() |
Formats:
|
||||||||||||||||||||
Copyright The Biochemical Society, London Plasma-membrane-associated sialidase (NEU3) differentially regulates integrin-mediated cell proliferation through laminin- and fibronectin-derived signalling *Division of Biochemistry, Miyagi Cancer Center Research Institute, Natori 981-1293, Japan †Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012, Japan ‡Department of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan §Division of Cell Biology, Kihara Institute for Biological Research and Graduate School of Integrated Sciences, Yokohama City University, Yokohama 244-0813, Japan Division of Head and Neck Surgery, Miyagi Cancer Center, Natori 981-1293, Japan1To whom correspondence should be addressed, at the Division of Biochemistry, Miyagi Cancer Center Research Institute, Natori 981-1293, Japan (email miyagi-ta173/at/pref.miyagi.jp). Received May 4, 2005; Revised September 26, 2005; Accepted October 24, 2005. This article has been cited by other articles in PMC.Abstract We have found previously that human plasma-membrane-associated sialidase (NEU3), a key glycosidase for ganglioside degradation, was markedly up-regulated in human colon cancers, with an involvement in suppression of apoptosis. To elucidate the molecular mechanisms underlying increased NEU3 expression, in the present study we investigated its role in cell adhesion of human colon cancer cells. DLD-1 cells transfected with NEU3 exhibited increased adhesion to laminins and consequent cell proliferation, but decreased cell adhesion to fibronectin and collagens I and IV, compared with control cells. When triggered by laminins, NEU3 clearly stimulated phosphorylation of FAK (focal adhesion kinase) and ERK (extracellular-signal-regulated kinase), whereas there was no activation on fibronectin. NEU3 markedly enhanced tyrosine phosphorylation of integrin β4 with recruitment of Shc and Grb-2 only on laminin-5, and NEU3 was co-immunoprecipitated by an anti-(integrin β4) antibody, suggesting that association of NEU3 with integrin β4 might facilitate promotion of the integrin-derived signalling on laminin-5. In addition, the promotion of phosphorylation of integrin β1 and ILK (integrin-linked kinase) was also observed on laminins. GM3 depletion as the result of NEU3 overexpression, assessed by TLC, appeared to be one of the causes of the increased adhesion on laminins and, in contrast, of the decreased adhesion on fibronectin – NEU3 probably having bimodal effects. These results indicate that NEU3 differentially regulates cell proliferation through integrin-mediated signalling depending on the extracellular matrix and, on laminins, NEU3 did indeed activate molecules often up-regulated in carcinogenesis, which may cause an acceleration of the malignant phenotype in cancer cells. Keywords: fibronectin, ganglioside, integrin, laminin-5, NEU3, sialidase Abbreviations: BrdU, bromodeoxyuridine; ECM, extracellular matrix; EHS, Engelbreth–Holm–Swarm tumour; ERK, extracellular-signal-regulated kinase; FAK, focal adhesion kinase; FBS, fetal bovine serum; HA, haemagglutinin; HGF, hepatocyte growth factor; HRP, horseradish peroxidase; ILK, integrin-linked kinase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide INTRODUCTION Cell interactions with the ECM (extracellular matrix) is crucial for essential biological processes such as adherence, migration, proliferation and differentiation, as well as survival [1,2]. Alterations in ECM components and the integrin family of receptors have been observed in various cancers [3,4], but their specific roles and regulatory mechanisms remain largely unclear. Ganglioside sialic-acid-containing glycosphingolipids present in cell-surface membranes are thought to make important contributions to cell-surface interactions and transmembrane signalling [5]. Altered sialylation of glycosphingolipids is observed in cancer as a ubiquitous phenotype, leading to the appearance of tumour-associated antigens, aberrant adhesion and blocking of transmembrane signalling [6]. Several reports have provided evidence that gangliosides are involved in cell adhesion to ECM through modulation of integrin functions. Ganglioside GM3 is required for adhesion of FUA169 cells to fibronectin through integrin α5β1 functions [7], promoting interactions of integrin α3 with tetraspanin CD9 in microdomains [8], and inhibiting the association of EGFR (epidermal growth factor receptor) with integrin β1 [9] and of integrin α5β1 with MMP-9 (matrix metalloproteinase-9) [10]. Gangliosides are metabolically regulated by the functional balance between sialidases and sialyltransferases that are responsible for their degradation and synthesis respectively. To understand the pathological significance of aberrant alterations of gangliosides in cancer, we have been focusing on sialidases of mammalian origin. The four forms, abbreviated to Neu1, Neu2, Neu3 and Neu4 [11,12], differ in their major subcellular localizations and substrate specificities, although their functional roles are not fully understood. Plasma-membrane-associated sialidase (Neu3) is a key enzyme for ganglioside hydrolysis. To obtain functional evidence regarding Neu3, we cloned and characterized sialidase cDNAs of mammalian origin previously [13–15]. In the present study we have employed a human orthologue NEU3 cDNA [14]. Consistent with the frequent aberrant expression of gangliosides in cancer, we have demonstrated previously [16] a remarkable up-regulation of the human plasma-membrane-associated sialidase (NEU3) in colon cancers. Because of its unique character in specifically hydrolysing gangliosides at plasma membranes, it is likely to participate in cell-surface events through modulation of gangliosides. To shed light on the molecular mechanisms underlying the increased expression of NEU3 in colon cancer, in the present study we investigated the influence of NEU3 on integrin-mediated signalling in colon cancer cells and found promotion of cell adhesion and integrin signalling on laminins, but opposite effects on fibronectin, which could be of advantage to the progression of colon carcinoma cells. EXPERIMENTAL ECMs and antibodies Laminin from EHS (Engelbreth–Holm–Swarm tumour) and fibronectin from human plasma were purchased from Asahi Techno Glass. Laminin from human placenta was obtained from Sigma. Human recombinant laminin-5 was prepared and purified as described previously [17]. Neutralizing antibodies to integrins α3 (ASC-1), α6 (GoH3), β1 (6S6) and β4 (ASC-8; Chemicon) were used for adhesion inhibition assays and flow cytometric analyses. An antibody to integrin β4 (3E1) for immunoprecipitation and stimulation was also obtained from Chemicon. HRP (horseradish peroxidase)-conjugated anti-(mouse IgG1) antibodies, antibodies to integrin β1 for immunoprecipitation (MAR4) and immunoblotting (clone18) respectively, and antibodies to phosphotyrosine (PY20) and Shc, were obtained from BD Biosciences. Antibodies to FAK (focal adhesion kinase), integrin β4 and the transferrin receptor were obtained from Santa Cruz Biotechnology. The anti-phosphoserine antibody was from Sigma. Antibodies to phospho-threonine, phospho-ERK (Thr202/Tyr204; where ERK is extracellular-signal-regulated kinase), ERK, phospho-FAK (Tyr925) and phospho-Shc (Tyr317) were from Cell Signaling Technology. Antibodies to phospho-FAK (Tyr397) and ILK (integrin-linked kinase) were purchased from Upstate. The HRP-conjugated anti-(rat IgG) antibody was from Jackson Immuno-Research Laboratories. FITC-conjugated anti-(mouse Ig) and anti-(rat Ig) antibodies were obtained from Biosource; anti-HA (haemagglutinin) antibodies were from Roche Diagnostics; and monoclonal anti-GM3 antibodies (M2590) were from Nippon Biotest Laboratory. A monoclonal anti-NEU3 antibody, prepared as described previously [18], was subjected to HRP conjugation and was used for detection of endogenous NEU3. Cell culture and NEU3 transfection Human colon adenocarcinoma-derived DLD-1 cells (Health Science Research Sources Bank, Osaka, Japan), HCT-116 cells (A.T.C.C.) and Colo 205 cells (Cancer Cell Repository, Tohoku University, Sendai, Japan) were maintained at 37 °C with 5% CO2 in RPMI 1640 containing 10% (v/v) FBS (fetal bovine serum). Cell-culture dishes and plates were coated with fibronectin (10 μg/ml), EHS-laminin (20 μg/ml), human placenta laminin (1 μg/ml), human recombinant laminin-5 (0.5 μg/ml) or poly-D-lysine (30 μg/ml), incubated at 37 °C for 1 h or at 4 °C overnight, washed with PBS (pH 7.4) and overlaid with 1% (w/v) heat-denatured BSA at 37 °C for 1 h. Collagen I- and collagen IV-coated plates were purchased from BD Biosciences and were overlaid with BSA as described above. To obtain NEU3 stable transfectants, a NEU3 expression vector was constructed by subcloning the ORF (open reading frame) of human NEU3 cDNA into the pCEP4 expression plasmid vector (Invitrogen). The vector was then transfected into DLD-1 cells by Effectene™ (Qiagen). Positive clones were selected under hygromycin (250 μg/ml). For transient transfection, an expression plasmid, constructed by inserting HA-tagged NEU3 cDNA into the pCAGGS expression vector [19], was transfected transiently as described above. To determine sialidase activity, cells were sonicated in 9 vol. of PBS containing 1 mM EDTA and 0.5 mM PMSF, leupeptin and pepstatin, and centrifuged at 1000 g for 10 min. The supernatant (crude extract) was then used for the measurement of sialidase activity at pH 4.6 with mixed gangliosides from bovine brain (Sigma) as a substrate in the presence of Triton X-100. The released sialic acid was determined by the modified thiobarbituric acid method as described previously [13]. Protein concentrations were determined by dye-binding assay (Bio-Rad Laboratories). A unit of activity was defined as the amount of enzyme that cleaved 1 nmol of sialic acid. Flow-cytometric analyses Subconfluent cells were harvested by trypsinization, washed with PBS, resuspended in PBS containing 0.5% BSA and incubated with monoclonal anti-integrin antibodies or control mouse IgG (Santa Cruz Biotechnology) in 0.5% BSA for 30 min on ice. After washing twice with PBS, cells were incubated with FITC-conjugated secondary antibodies in 0.5% BSA for 30 min on ice. Cells were then washed twice with PBS and cell-surface integrins were determined using a flow cytometer (BD Biosciences). Cell-adhesion assays For cell-adhesion assays, a Cystal Violet colorimetric method was employed [20]. Briefly, subconfluent cells were harvested by trypsinization, washed and suspended in serum-free medium containing 0.1% BSA at 1×106 cells/ml, then plated on 96-well cell-culture plates coated with ECM and incubated at 37 °C for 15–60 min. Cell-culture plates were washed with PBS to remove unbound cells, fixed with 70% ethanol at 4 °C for 15 min, stained with 0.1% Crystal Violet (Sigma) at room temperature for 25 min and washed twice with distilled water. Crystal Violet in adherent cells was eluted with 10% (v/v) acetic acid, and cell adhesion was determined by A550 on a microplate reader (Corona Electric). In cell-adhesion-inhibition assays, suspended cells were incubated with 5 μg/ml neutralizing anti-integrin antibodies at 37 °C for 30 min before plating. In some experiments, cell-adhesion assays were performed at 4 °C to determine integrin α6β4-mediated cell adhesion [21]. To examine the effects of ganglioside GM3 on cell adhesion, cells were untreated or pretreated with GM3 (Alexis Biochemicals) at 50 μM in conditioned medium for 24 h at 37 °C and were assayed for cell adhesion. Cell-proliferation and DNA-synthesis assays Cell growth rate was measured using a modified MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay. Subconfluent cells were harvested, washed and suspended in serum-free medium at 3×104 cells/ml. Cells were seeded on to 96-well ECM-coated cell-culture plates at 100 μl/well and incubated at 37 °C. After 0–96 h, WST-1 reagent was added, incubated for 1 h at 37 °C, and formazan produced by live cells was measured with a microplate reader at A450 (reference A630). DNA synthesis was determined by BrdU (bromodeoxyuridine) incorporation using a BrdU Labeling and Detection kit III (Roche Diagnostics). Cells, seeded on 96-well plates as above, were incubated at 37 °C for 16 h, and BrdU was then added to the cell culture. After incubation for a further 4 h, incorporated BrdU was detected according to the manufacturer's instructions. Immunoprecipitation and immunoblotting Subconfluent cells maintained in serum-free medium for 20–24 h were harvested and suspended in serum-free medium under rotation at 37 °C for 45 min. Cells were allowed to adhere for 15–60 min to cell-culture dishes coated with ECM as described above. After incubation, dishes were rinsed with PBS to remove unattached cells and the adherent cells were extracted with modified RIPA buffer [50 mM Hepes (pH 7.5), 150 mM NaCl, 1% Nonidet P40, 2 mM EDTA, 7.5 μg/ml aprotinin, 10 μg/ml leupeptin, 10 mM NaF, 2 mM orthovanadate, 0.25% sodium deoxycholate and 2 mM PMSF] for 30 min on ice. Suspended cells without adhesion were used as the controls. Lysates were briefly sonicated and precleared with centrifugation at 1000 g for 10 min before use. Protein-matched samples were added to anti-(integrin β1) or -(integrin β4) antibodies and incubated at 4 °C for 30 min (integrin β4) or 2 h (integrin β1). Protein G–Sepharose (Amersham Biosciences) was then added and immunoprecipitation was continued for another 3 h (integrin β4) or overnight (integrin β1) at 4 °C. The immunoprecipitates were separated by SDS/PAGE and were transferred on to PVDF membranes (Amersham Biosciences). Transferred proteins were detected with specific antibodies by ECL® (enhanced chemiluminescence) (Amersham Biosciences) and a CCD (charged coupled device) imaging system (Bio-Rad Laboratories). Densitometric analyses were performed with Scion Image and Quantity One software (Bio-Rad Laboratories). In the immunoprecipitation of NEU3 with the anti-(integrin β4) antibody, 24 h after transient transfection with HA-tagged NEU3, cells were cultured for a further 24 h under serum depletion and then plated on to laminin-5. The cells harvested were lysed and subjected to immunoprecipitation with the anti-(integrin β4) antibody. NEU3 and Grb2 were detected in the immunoprecipitates with anti-HA and anti-Grb2 antibodies respectively. Endogenous NEU3 was detected with an HRP-conjugated anti-NEU3 antibody. TLC The glycolipid pattern was analysed by TLC. From 107 cells, glycolipids were extracted with 2 ml of propan-2-ol/hexane/water (11:5:4, by vol.) and hydrolysed phospholipids with 0.1 M NaOH/methanol. After desalting with a SEP-PAK C18 cartridge, total lipid extracts were applied to DEAE–Sephadex A25 minicolumns. Neutral glycolipids were eluted with chloroform/methanol/water (15:30:4, by vol.) and acidic glycolipids with chloroform/methanol/2 M sodium acetate (15:30:4, by vol.). After dialysis, equal amounts of each sample were applied on to HPLC plates (Baker). Neutral glycolipids were separated by chromatography in a solvent system of chloroform/methanol/0.02% aqueous CaCl2 (60:40:9, by vol.), and acidic glycolipids by chromatography in chloroform/methanol/0.02% aqueous CaCl2 (60:35:8, by vol.). Both were visualized with orcinol/H2SO4. TLC immunostaining was performed using monoclonal anti-GM3 antibodies and an avidin–biotin immunoperoxidase staining kit (Vector). RESULTS NEU3 promotes cell adhesion to laminins Human colon cancer DLD-1 cells were stably transfected with NEU3 cDNA (Figure 1
NEU3 promotes cell proliferation on laminins Results for cell growth on matrix proteins, as examined by MTT assay, are shown in Figure 4
NEU3 promotes integrin-mediated signalling on laminins and facilitates the formation of a Shc–Grb2 complex To investigate the molecular mechanisms underlying the differential effects of NEU3 on laminins and fibronectin, the phosphorylation levels of molecules involved in integrin-mediated signalling were evaluated. As shown in Figure 5
We then evaluated the tyrosine phosphorylation of Shc, an adaptor protein in another major tyrosine-kinase-dependent pathway activated by integrins which is often constitutively activated in tumours [27]. The level was relatively high, even without adhesion, and was increased by NEU3 transfection in the cells on laminin-5, but the cells on EHS-laminin and fibronectin had decreased Shc phosphorylation (Figure 5
Possible involvement of gangliosides in cell adhesion Finally, we examined the possible mechanisms of an alteration in integrin-mediated signalling caused by NEU3 overexpression. To determine whether glycolipids produced as the result of NEU3 enzyme activity actually affect cell adhesion, glycolipids from DLD-1 cells employed in the experiments were analysed by TLC. In addition to a slight increase in lactosylceramide in neutral glycolipid fractions (results not shown), NEU3 transfectants had a significant decrease in GM3 gangliosides compared with control cells in the acidic glycolipid fractions (Figure 7
DISCUSSION The present study provides the first evidence that plasma-membrane-associated sialidase (NEU3) promotes cell adhesion to laminins, integrin-mediated signalling to ERK and subsequent activation of cell proliferation, but attenuates adhesion to fibronectin and its related signalling. Among the three types of laminins tested, only laminin-5, a major ligand for integrin α6β4, contributed to Shc phosphorylation in addition to FAK phosphorylation; NEU3 enhancing both adhesion-dependent and -independent tyrosine phosphorylation of integrin β4 and Shc, recruitment of Grb2 and ERK phosphorylation. Although the distinct roles of Shc and FAK in ERK activation are not fully understood, they have been suggested to participate in early and persistent events respectively [30]. NEU3 overexpression may thus contribute to enhance and sustained ERK activation through Shc and FAK signalling when cells are attached to laminin-5, leading to adhesion-dependent cell proliferation. ERK phosphorylation on EHS-laminin appeared to be relatively modest (Figure 5
Our present results suggest further that GM3 depletion by NEU3 may be one of the causes of stimulation of cell adhesion and proliferation mediated by integrins α3β1 and α6β1 through increased integrin β1 phosphorylation, but suppression of integrin α5β1-mediated signalling (Figure 6 In direct contrast with our present results, there have been several studies reporting that adhesion to fibronectin is promoted by GM3 depletion in SSC cells [10] and IdI cells [8]. However, other reports have described that GM3 depletion inhibits cell adhesion to fibronectin in rat hepatoma cells [34] and mouse mammary carcinoma cells [7]. In the present study, we have shown a reduction in ILK phosphorylation by cells on fibronectin, in contrast with its activation by GM3 depletion in SSC cells [35]. It is necessary to elucidate why and how NEU3 displays differential effects, and this presumably occurs through recognition of individual integrin receptors. In this context, it is of interest that increased adhesion on laminins and the decrease on fibronectin by NEU3 overexpression was also observed in oral squamous cell carcinoma cells HSC-2 (K. Kato, K. Shiga and T. Miyagi, unpublished work). This indicates that NEU3 might induce these phenomena independently of cell type, via modulation of signalling by interacting with signalling molecules, such as integrin β4, in addition to changing ganglioside patterns. We have found previously a remarkable increase in expression of NEU3 in colon cancer tissues compared with adjacent non-cancerous tissues at both the mRNA and enzyme activity levels [16]. Moreover, the present results clearly indicate that NEU3 is indeed involved in activation of signalling molecules, including FAK [24,25], ILK [28], Shc [27], integrin β4 [3,36] and also Met [33], often up-regulated in carcinogenesis. Among matrix proteins, laminins have been implicated in an increase in the malignant phenotype of tumour cells. Neo-expression of laminin-5 is associated with proliferation of carcinoma cells and this ECM element often accumulates in invading edges of carcinomas [3]. Integrins α3β1 and α6β4 are cell-surface receptors acting with laminin-5. By contrast, fibronectin has been shown to reduce progression of carcinomas [37,38]. Since there were no significant differences in expression level of integrin receptors between NEU3 transfectants and control cells in the present study, NEU3 might function distinctly with individual integrins. In fact, NEU3 does not activate, but rather attenuates, integrin-α5β1-mediated signalling. From the present results, elevated expression of NEU3 in colon cancer may cause tumour progression through further activation of molecules that are up-regulated on adhesion to laminins which usually accumulate in this type of cancer. In contrast, NEU3 might negatively regulate signalling on fibronectin, resulting in suppression of cell adhesion, proliferation and migration. It should be borne in mind that NEU3 elevation is characteristic in cancer and found in a wide spectrum of lesions, including tumours of the digestive system (K. Shiga, K. Kato, T. Wada and T. Miyagi, unpublished work). The molecular mechanisms and significance of increased expression of NEU3 in cancer could be targeted with the hope of providing valuable information for diagnosis and therapy. Acknowledgments We thank Ms Setsuko Moriya for expert technical assistance. This study was supported in part by Grants-in-Aid from Kurokawa Cancer Research Foundation and by a Grant-in-Aid of The Japan Medical Association. References 1. Hynes R. O. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673–687. [PubMed] 2. Calderwood D. A. Integrin activation. J. Cell Sci. 2004;117:657–666. [PubMed] 3. Lohi J. Laminin-5 in the progression of carcinomas. Int. J. Cancer. 2001;94:763–767. [PubMed] 4. Engbring J. A., Kleinman H. K. The basement membrane matrix in malignancy. J. Pathol. 2003;200:465–470. [PubMed] 5. Hakomori S., Yamamura S., Handa K. Signal transduction through glyco (sphingo) lipids. Introduction and recent studies on glyco (sphingo) lipid-enriched microdomains. Ann. N.Y. Acad. Sci. 1998;845:1–10. [PubMed] 6. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo (glyco) lipid metabolism. Cancer Res. 1996;56:5309–5318. [PubMed] 7. Zheng M., Fang H., Tsuruoka T., Tsuji T., Sasaki T., Hakomori S. Regulatory role of GM3 ganglioside in α5β1 integrin receptor for fibronectin-mediated adhesion of FUA169 cells. J. Biol. Chem. 1993;268:2217–2222. [PubMed] 8. Kawakami Y., Kawakami K., Steelant W. F., Ono M., Baek R. C., Handa K., Withers D. A., Hakomori S. Tetraspanin CD9 is a ‘proteolipid’ and its interaction with α3 integrin in microdomain is promoted by GM3 ganglioside, leading to inhibition of laminin-5-dependent cell motility. J. Biol. Chem. 2002;277:34349–34358. [PubMed] 9. Wang X. Q., Sun P., Paller A. S. Ganglioside GM3 blocks the activation of epidermal growth factor receptor induced by integrin at specific tyrosine sites. J. Biol. Chem. 2003;278:48770–48778. [PubMed] 10. Wang X. Q., Sun P., Paller A. S. Ganglioside GM3 inhibits matrix metalloproteinase-9 activation and disrupts its association with integrin. J. Biol. Chem. 2003;278:25591–25599. [PubMed] 11. Monti E., Preti A., Venerando B., Borsani G. Recent development in mammalian sialidase molecular biology. Neurochem. Res. 2002;27:649–663. [PubMed] 12. Miyagi T., Kato K., Ueno S., Wada T. Aberrant expression of sialidase in cancer. Trends Glycosci. Glycotechnol. 2004;92:371–381. 13. Miyagi T., Wada T., Iwamatsu A., Hata K., Yoshikawa Y., Tokuyama S., Sawada M. Molecular cloning and characterization of a plasma membrane-associated sialidase specific for gangliosides. J. Biol. Chem. 1999;274:5004–5011. [PubMed] 14. Wada T., Yoshikawa Y., Tokuyama S., Kuwabara M., Akita H., Miyagi T. Cloning, expression and chromosomal mapping of a human ganglioside sialidase. Biochem. Biophys. Res. Commun. 1999;261:21–27. [PubMed] 15. Hasegawa T., Yamaguchi K., Wada T., Takeda A., Itoyama Y., Miyagi T. Cloning, expression, and chromosomal mapping of a human ganglioside sialidase. J. Biol. Chem. 2000;275:8007–8015. [PubMed] 16. Kakugawa Y., Wada T., Yamaguchi K., Yamanami H., Ouchi K., Sato I., Miyagi T. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc. Natl. Acad. Sci. U.S.A. 2002;99:10718–10723. [PubMed] 17. Kariya Y., Ishida K., Tsubota Y., Nakashima Y., Hirosaki T., Ogawa T., Miyazaki K. Efficient expression system of human recombinant laminin-5. J. Biochem. (Tokyo). 2002;132:607–612. [PubMed] 18. Wang Y., Yamaguchi K., Wada T., Hata K., Zhao X., Fujimoto T., Miyagi T. A close association of the ganglioside-specific sialidase Neu3 with caveolin in membrane microdomains. J. Biol. Chem. 2002;277:26252–26259. [PubMed] 19. Niwa H., Yamamura K., Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991;108:193–200. [PubMed] 20. Orian-Rousseau V., Aberdam D., Rousselle P., Messent A., Gavrilovic J., Meneguzzi G., Kedinger M., Simon-Assmann P. Human colonic cancer cells synthesize and adhere to laminin-5. Their adhesion to laminin-5 involves multiple receptors among which is integrin α2β1. J. Cell Sci. 1998;111:1193–2004. 21. Russell A. J., Fincher E. F., Millman L., Smith R., Vela V., Waterman E. A., Dey C. N., Guide S., Weaver V. M., Marinkovich M. P. α6β4 integrin regulates keratinocyte chemotaxis through differential GTPase activation and antagonism of α3β1 integrin. J. Cell Sci. 2003;116:3543–3556. [PubMed] 22. Niessen C. M., Hogervorst F., Jaspars L. H., de Melker A. A., Delwel G. O., Hulsman E. H., Kuikman I., Sonnenberg A. The α6β4 integrin is a receptor for both laminin and kalinin. Exp. Cell Res. 1994;211:360–367. [PubMed] 23. Rousselle P., Aumailley M. Kalinin is more efficient than laminin in promoting adhesion of primary keratinocytes and some other epithelial cells and has a different requirement for integrin receptors. J. Cell Biol. 1994;125:205–214. [PubMed] 24. Weiner T. M., Liu E. T., Craven R. J., Cance W. G. Expression of focal adhesion kinase gene and invasive cancer. Lancet. 1993;342:1024–1025. [PubMed] 25. Owens L. V., Xu L., Craven R. J., Dent G. A., Weiner T. M., Kornberg L., Liu E. T., Cance W. G. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 1995;55:2752–2755. [PubMed] 26. Kikkawa Y., Sanzen N., Fujiwa H., Sonnenberg A., Sekiguchi K. Integrin binding specificity of laminin-10/11: laminin-10/11 are recognized by α3β1, α6β1 and α6β4 integrins. J. Cell Sci. 2000;113:869–876. [PubMed] 27. Pelicci G., Lanfrancone L., Salcini A. E., Romano A., Mele S., Grazia Borrello M., Segatto O., Di Fiore P. P., Pelicci P. G. Constitutive phosphorylation of Shc proteins in human tumors. Oncogene. 1995;11:899–907. [PubMed] 28. Persad S., Dedhar S. The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Rev. 2003;22:375–384. [PubMed] 29. Mainiero F., Pepe A., Wary K. K., Spinardi L., Mohammadi M., Schlessinger J., Giancotti F. G. Signal transduction by the α6β4 integrin: distinct β4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes. EMBO J. 1995;14:4470–4481. [PubMed] 30. Barberis L., Wary K. K., Fiucci G., Liu F., Hirsch E., Brancaccio M., Altruda F., Tarone G., Giancotti F. G. Distinct roles of the adaptor protein Shc and focal adhesion kinase in integrin signaling to ERK. J. Biol. Chem. 2000;275:36532–36540. [PubMed] 31. Sasaki T., Hata H., Suzuki S., Sawada M., Wada T., Tateno H., Obinata M., Suzuki Y., Miyagi T. Overexpression of plasma membrane-associated sialidase attenuates insulin signaling in transgenic mice. J. Biol. Chem. 2003;278:27896–27902. [PubMed] 32. Gagnoux-Palacios L., Dans M., van't Hof W., Mariotti A., Pepe A., Meneguzzi G., Resh M. D., Giancotti F. G. Compartmentalization of integrin α6β4 signaling in lipid rafts. J. Cell Biol. 2003;162:1189–1196. [PubMed] 33. Trusolino L., Bertotti A., Comoglio P. M. A signaling adaptor function for α6β4 integrin in the control of HGF-dependent invasive growth. Cell. 2001;107:643–654. [PubMed] 34. Barletta E., Mugnai G., Ruggieri S. Complex gangliosides modulate the integrin-mediated adhesion in a rat hepatoma cell line. Biochem. Biophys. Res. Commun. 1993;192:214–222. [PubMed] 35. Wang X. Q., Sun P., Paller A. S. Inhibition of integrin-linked kinase/protein kinase B/Akt signaling: mechanism for ganglioside-induced apoptosis. J. Biol. Chem. 2001;276:44504–44511. [PubMed] 36. Dajee M., Lazarov M., Zhang J. Y., Cai T., Green C. L., Russell A. J., Marinkovich M. P., Tao S., Lin Q., Kubo Y., Khavari P. A. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature (London). 2003;421:594–595. 37. Akiyama S. K., Olden K., Yamada K. M. Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev. 1995;14:173–189. [PubMed] 38. Taverna D., Ullman-Cullere M., Rayburn H., Bronson R. T., Hynes R. O. A test of the role of α5 integrin/fibronectin interactions in tumorigenesis. Cancer Res. 1998;58:848–853. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||
Cell. 2002 Sep 20; 110(6):673-87.
[Cell. 2002]J Cell Sci. 2004 Feb 15; 117(Pt 5):657-66.
[J Cell Sci. 2004]Int J Cancer. 2001 Dec 15; 94(6):763-7.
[Int J Cancer. 2001]J Pathol. 2003 Jul; 200(4):465-70.
[J Pathol. 2003]Ann N Y Acad Sci. 1998 Jun 19; 845():1-10.
[Ann N Y Acad Sci. 1998]Neurochem Res. 2002 Aug; 27(7-8):649-63.
[Neurochem Res. 2002]J Biol Chem. 1999 Feb 19; 274(8):5004-11.
[J Biol Chem. 1999]J Biol Chem. 2000 Mar 17; 275(11):8007-15.
[J Biol Chem. 2000]Biochem Biophys Res Commun. 1999 Jul 22; 261(1):21-7.
[Biochem Biophys Res Commun. 1999]Proc Natl Acad Sci U S A. 2002 Aug 6; 99(16):10718-23.
[Proc Natl Acad Sci U S A. 2002]J Biochem. 2002 Oct; 132(4):607-12.
[J Biochem. 2002]J Biol Chem. 2002 Jul 19; 277(29):26252-9.
[J Biol Chem. 2002]Gene. 1991 Dec 15; 108(2):193-9.
[Gene. 1991]J Biol Chem. 1999 Feb 19; 274(8):5004-11.
[J Biol Chem. 1999]J Cell Sci. 2003 Sep 1; 116(Pt 17):3543-56.
[J Cell Sci. 2003]J Biochem. 2002 Oct; 132(4):607-12.
[J Biochem. 2002]Int J Cancer. 2001 Dec 15; 94(6):763-7.
[Int J Cancer. 2001]J Cell Sci. 2003 Sep 1; 116(Pt 17):3543-56.
[J Cell Sci. 2003]Exp Cell Res. 1994 Apr; 211(2):360-7.
[Exp Cell Res. 1994]J Cell Biol. 1994 Apr; 125(1):205-14.
[J Cell Biol. 1994]Lancet. 1993 Oct 23; 342(8878):1024-5.
[Lancet. 1993]Cancer Res. 1995 Jul 1; 55(13):2752-5.
[Cancer Res. 1995]J Cell Sci. 2000 Mar; 113 ( Pt 5)():869-76.
[J Cell Sci. 2000]Oncogene. 1995 Sep 7; 11(5):899-907.
[Oncogene. 1995]Exp Cell Res. 1994 Apr; 211(2):360-7.
[Exp Cell Res. 1994]J Cell Biol. 1994 Apr; 125(1):205-14.
[J Cell Biol. 1994]Cancer Metastasis Rev. 2003 Dec; 22(4):375-84.
[Cancer Metastasis Rev. 2003]EMBO J. 1995 Sep 15; 14(18):4470-81.
[EMBO J. 1995]J Biol Chem. 2000 Nov 24; 275(47):36532-40.
[J Biol Chem. 2000]J Biol Chem. 2002 Jul 19; 277(29):26252-9.
[J Biol Chem. 2002]J Biol Chem. 2003 Jul 25; 278(30):27896-902.
[J Biol Chem. 2003]J Cell Biol. 2003 Sep 29; 162(7):1189-96.
[J Cell Biol. 2003]Cell. 2001 Nov 30; 107(5):643-54.
[Cell. 2001]J Biol Chem. 2003 Jul 11; 278(28):25591-9.
[J Biol Chem. 2003]J Biol Chem. 2002 Sep 13; 277(37):34349-58.
[J Biol Chem. 2002]Biochem Biophys Res Commun. 1993 Apr 15; 192(1):214-22.
[Biochem Biophys Res Commun. 1993]J Biol Chem. 1993 Jan 25; 268(3):2217-22.
[J Biol Chem. 1993]J Biol Chem. 2001 Nov 30; 276(48):44504-11.
[J Biol Chem. 2001]Proc Natl Acad Sci U S A. 2002 Aug 6; 99(16):10718-23.
[Proc Natl Acad Sci U S A. 2002]Lancet. 1993 Oct 23; 342(8878):1024-5.
[Lancet. 1993]Cancer Res. 1995 Jul 1; 55(13):2752-5.
[Cancer Res. 1995]Cancer Metastasis Rev. 2003 Dec; 22(4):375-84.
[Cancer Metastasis Rev. 2003]Oncogene. 1995 Sep 7; 11(5):899-907.
[Oncogene. 1995]